Celyad SA (NASDAQ:CYAD) has been assigned an average broker rating score of 1.67 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Celyad SA’s rating score has declined by 11.3% from three months ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a 1-year consensus price target of $49.00 for the company, according to Zacks. Zacks has also assigned Celyad SA an industry rank of 105 out of 265 based on the ratings given to related companies.

An institutional investor recently raised its position in Celyad SA stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Celyad SA (NASDAQ:CYAD) by 24.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,161 shares of the company’s stock after buying an additional 3,426 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank owned 0.18% of Celyad SA worth $429,000 at the end of the most recent quarter. 4.55% of the stock is currently owned by institutional investors.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/celyad-sa-cyad-given-average-recommendation-of-buy-by-brokerages.html

Shares of Celyad SA (NASDAQ:CYAD) remained flat at $18.72 during trading on Wednesday. 150 shares of the stock were exchanged. Celyad SA has a 52-week low of $18.72 and a 52-week high of $59.50. The stock’s market cap is $174.34 million. The firm has a 50 day moving average price of $21.70 and a 200 day moving average price of $34.56.

Celyad SA Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

5 Day Chart for NASDAQ:CYAD

Get a free copy of the Zacks research report on Celyad SA (CYAD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with MarketBeat.com's FREE daily email newsletter.